Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pimavanserin for Psychosis Associated with Alzheimer's Disease: Double-Blind, Placebo-Controlled Phase 2 Trial
2010-020008-31Phase 2Completed
- Sponsor
- Acadia Pharmaceuticals
- Start
- Aug 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Alzheimer's disease psychosis (ADP) and Alzheimer's disease (AD) comparing Pimavanserin 40 mg with Placebo (2 arms). Primary endpoints: Key efficacy endpoint and Safety and tolerability. Started Aug 2010; status: completed.
02
Drugs
pimavanserin
03
Conditions
Alzheimer's disease psychosis (ADP)Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2010-020008-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-020008-31.